EMBECTA CORP. Selling, General and Administrative Expense
EMBECTA CORP. (EMBC) reported Selling, General and Administrative Expense of $78.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-07
- EMBECTA CORP. selling, general and administrative expense for the quarter ending 2026-06-30 was $78.60M, a 6.87% decline year-over-year.
- EMBECTA CORP. selling, general and administrative expense for the quarter ending 2026-03-31 was $76.20M, a 4.27% decline year-over-year.
- EMBECTA CORP. selling, general and administrative expense for the quarter ending 2025-12-31 was $77.60M, a 4.32% decline year-over-year.
- EMBECTA CORP. selling, general and administrative expense for the quarter ending 2025-09-30 was $86.90M, a 10.23% decline year-over-year.
- EMBECTA CORP. selling, general and administrative expense for fiscal 2025 was $332.00M, a 9.07% decline from fiscal 2024.
- EMBECTA CORP. selling, general and administrative expense for fiscal 2024 was $365.10M, a 6.97% increase from fiscal 2023.
- EMBECTA CORP. selling, general and administrative expense for fiscal 2023 was $341.30M, a 15.77% increase from fiscal 2022.
- EMBECTA CORP. selling, general and administrative expense for fiscal 2022 was $294.80M, a 22.68% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $78.60M 10-Q · filed 2026-08-07 | $154.80M derived: sum of 2 quarters · filed 2026-08-07 | $232.40M 10-Q · filed 2026-08-07 | $319.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $76.20M 10-Q · filed 2026-05-05 | $153.80M 10-Q · filed 2026-05-05 | $240.70M derived: sum of 3 quarters · filed 2026-05-05 | $325.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $77.60M 10-Q · filed 2026-02-05 | $164.50M derived: sum of 2 quarters · filed 2026-02-05 | $248.90M derived: sum of 3 quarters · filed 2026-08-07 | $328.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $86.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $171.30M derived: sum of 2 quarters · filed 2026-08-07 | $250.90M derived: sum of 3 quarters · filed 2026-08-07 | $332.00M 10-K · filed 2025-11-25 |
| 2025-06-30 | $84.40M 10-Q · filed 2026-08-07 | $164.00M derived: sum of 2 quarters · filed 2026-08-07 | $245.10M 10-Q · filed 2026-08-07 | $341.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $79.60M 10-Q · filed 2026-05-05 | $160.70M 10-Q · filed 2026-05-05 | $257.50M derived: sum of 3 quarters · filed 2026-05-05 | $343.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $81.10M 10-Q · filed 2026-02-05 | $177.90M derived: sum of 2 quarters · filed 2026-02-05 | $263.60M derived: sum of 3 quarters · filed 2026-02-05 | $355.90M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $96.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $182.50M derived: sum of 2 quarters · filed 2025-11-25 | $274.80M derived: sum of 3 quarters · filed 2025-11-25 | $365.10M 10-K · filed 2025-11-25 |
| 2024-06-30 | $85.70M 10-Q · filed 2025-08-08 | $178.00M derived: sum of 2 quarters · filed 2025-08-08 | $268.30M 10-Q · filed 2025-08-08 | $364.00M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $92.30M 10-Q · filed 2025-05-09 | $182.60M 10-Q · filed 2025-05-09 | $278.30M derived: sum of 3 quarters · filed 2025-11-25 | $365.90M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $90.30M 10-Q · filed 2025-02-06 | $186.00M derived: sum of 2 quarters · filed 2025-11-25 | $273.60M derived: sum of 3 quarters · filed 2025-11-25 | $358.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $95.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $183.30M derived: sum of 2 quarters · filed 2025-11-25 | $268.50M derived: sum of 3 quarters · filed 2025-11-25 | $341.30M 10-K · filed 2025-11-25 |
| 2023-06-30 | $87.60M 10-Q · filed 2024-08-09 | $172.80M derived: sum of 2 quarters · filed 2024-08-09 | $245.60M 10-Q · filed 2024-08-09 | $327.50M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $85.20M 10-Q · filed 2024-05-09 | $158.00M 10-Q · filed 2024-05-09 | $239.90M derived: sum of 3 quarters · filed 2024-12-11 | $323.70M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $72.80M 10-Q · filed 2024-02-09 | $154.70M derived: sum of 2 quarters · filed 2024-12-11 | $238.50M derived: sum of 3 quarters · filed 2024-12-11 | $305.40M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $81.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $165.70M derived: sum of 2 quarters · filed 2024-12-11 | $232.60M derived: sum of 3 quarters · filed 2024-12-11 | $294.80M 10-K · filed 2024-12-11 |
| 2022-06-30 | $83.80M 10-Q · filed 2023-08-08 | $150.70M derived: sum of 2 quarters · filed 2023-08-08 | $212.90M 10-Q · filed 2023-08-08 | $283.70M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $66.90M 10-Q · filed 2023-05-12 | $129.10M 10-Q · filed 2023-05-12 | $199.90M derived: sum of 3 quarters · filed 2023-11-29 | $260.40M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $62.20M 10-Q · filed 2023-02-14 | $133.00M derived: sum of 2 quarters · filed 2023-11-29 | $193.50M derived: sum of 3 quarters · filed 2023-11-29 | $249.30M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $70.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $131.30M derived: sum of 2 quarters · filed 2023-11-29 | $187.10M derived: sum of 3 quarters · filed 2023-11-29 | $240.30M 10-K · filed 2023-11-29 |
| 2021-06-30 | $60.50M 10-Q · filed 2022-08-15 | $116.30M derived: sum of 2 quarters · filed 2022-08-15 | $169.50M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $55.80M 10-Q · filed 2022-05-13 | $109.00M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $53.20M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $214.70M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |